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oronary Intervention
ithout a Safety Net*
arold L. Dauerman, MD, FACC
urlington, Vermont
he words “randomized clinical trial” may seem to present
n unassailable truth (1). In this issue of the Journal, Stabile
t al. (2) present the CIAO (Coronary Interventions
ntiplatelet-based Only) randomized clinical trial with the
ollowing abstract conclusion: “In the treatment of uncom-
licated lesions and in the presence of dual antiplatelet
herapy, elective percutaneous coronary intervention (PCI)
an be safely performed without systemic anticoagulation
nd is associated with a reduced incidence of bleeding
omplications.” The authors are to be congratulated for
xamining a new PCI pharmacology regimen in a random-
zed clinical trial. But despite the randomized examination
nd thought-provoking conclusion, might there be a signif-
cant clinical risk in abandoning the time-tested approach of
ombined antiplatelet and antithrombotic therapy for elec-
ive PCI?
See page 1293
athophysiology of elective percutaneous coronary inter-
ention. The CIAO trial randomly allocated 700 patients
ndergoing elective PCI to dual oral antiplatelet therapy
ersus dual oral antiplatelet therapy plus unfractionated
eparin: major adverse cardiovascular events were similar at
0 days (3.7% vs. 2.0%, p  0.17 for control group vs. no
eparin group). One interpretation of the CIAO trial is that
hrombus generation is not a critical component of elective
CI, and thus intravenous antithrombotic therapy is not
eeded. Thrombus presence and generation is critical in the
etting of PCI for acute coronary syndromes: angioscopy
nd intravascular ultrasonography have demonstrated
hrombus and/or plaque rupture in more than two-thirds of
atients with acute coronary syndromes (3,4). As seen in the
cute coronary syndrome patients of the OASIS (Optimal
ntiplatelet Strategy for Interventions)-5 trial and the
Editorials published in the Journal of the American College of Cardiology reflect the
iews of the authors and do not necessarily represent the views of JACC or the
merican College of Cardiology.
From the University of Vermont College of Medicine, Burlington, Vermont. Dr.
auerman is on the steering committee for the CHAMPION PCI (Cangrelor versush
tandard Therapy to Achieve Optimal Management of Platelet Inhibition, Percuta-
eous Coronary Intervention) trial and is a consultant to The Medicines Company.EST (Which Early ST-Elevation Myocardial Infarction
herapy) trial, inadequate thrombin inhibition with
ondaparinux and enoxaparin during the PCI procedure led
o catheter thrombus and a need for supplemental unfrac-
ionated heparin (5,6).
But elective PCI has a potential thrombotic component
s well. In angioscopy studies of patients presenting with
table angina, intracoronary thrombus may be seen in 17%
o 65% of patients (3,7). Similarly, complex plaque rupture
ay be found in 19% to 35% of patients with stable angina
ndergoing elective PCI (4,8). Furthermore, stenting itself
enerates early thrombotic and inflammatory responses
9,10). Thus, pre-existing thrombus, thrombus generation,
latelet activation, and systemic inflammation are part of all
CI procedures, and the designation “elective” lessens but
oes not eliminate the consequences of this pathophysiology.
harmacology of elective coronary intervention. If the
athophysiology of elective PCI may still involve thrombus,
hen the CIAO trial challenges us to accept a new thera-
eutic paradigm: potent inhibition of platelet activation and
ggregation will decrease thrombin generation so pro-
oundly that any form of intravenous antithrombin therapy
s obviated. This concept is supported by 1 single-center
egistry and the randomized REMOVE (Reduction in
ajor and Minor Adverse Events With Eptifibatide-Based
harmacotherapy in Percutaneous Coronary Intervention)
linical trial (n 180) in which elective PCI was performed
ith aspirin, clopidogrel, and glycoprotein IIb/IIIa inhibi-
ors with no significant increased risk of ischemic events as
ompared with patients who also received unfractionated
eparin (11,12). Similarly, recent analyses of stent trials
ave challenged the prior assumptions on heparin dosing
13) and have not clearly identified a lower limit for
ctivated clotting time (14). But the CIAO trial takes us to
n extreme never before examined: it states that we do not
ven need a potent glycoprotein receptor inhibitor to indi-
ectly suppress thrombin generation. Rather, aspirin and
hienopyridine alone can prevent pre-existing, contact- and
tent-mediated thrombus formation from generating isch-
mic complications. This hypothesis is put forward even in
he setting of significant known variations in individual
esponsiveness to oral antiplatelet therapy (15).
This is a concerning hypothesis. First, the protocol of the
EMOVE trial had to be amended because of spontaneous
hrombus formation during elective bifurcation lesion PCI
despite use of a glycoprotein receptor inhibitor), suggesting
pre-existing recognition of clinical risk in the “no anti-
hrombin” approach (12). Second, the investigators appro-
riately recognized that there would be a low ischemic
omplication rate (2.5%) in the selected elective PCI pop-
lation. But, the upper margin for defining noninferiority in
he CIAO trial is more than double the event rate for the
ontrol group—thus, one could have a 5.4% ischemic
omplication rate in the tested group and a 2.5% rate in the
eparin group and still meet noninferiority criteria.
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PCI Pharmacology Options October 14, 2008:1299–301The upper margin to define noninferiority in other PCI
harmacology trials is usually in the range of 25% to 50%
igher than the point estimate for the event in the control
roup (16). The CIAO trial’s liberal definition of noninfe-
iority has a basis in reality: to do a noninferiority trial with
n ischemic complication rate of 2.5% and an upper margin
5% higher than the control group, one would have to
andomize more than 30,000 patients to prove aspirin/
lopidigrel alone regimens are noninferior to aspirin/
lopidogrel/heparin-based regimens.
Finally, was the tested group (aspirin/clopidogrel alone)
uperior to the control group (aspirin/clopidogrel/heparin)?
he potential benefits of removing heparin from elective PCI
re real: for example, unfractionated heparin is a first-
eneration antithrombin that may activate platelets (17), be
ontaminated (18), or increase bleeding complications (19).
lthough reduction of bleeding complications has clear merit
20), it is not clear that the CIAO trial demonstrates a
onsistent reduction in bleeding complications. Similar to the
EMOVE trial, a clear reduction in Thrombolysis In Myo-
ardial Infarction major or minor bleeding was not seen.
lthough other definitions suggest a bleeding reduction is
ossible, it does not reach the significance or consistency of
leeding reduction seen in comparing newer antithrombin
gents to heparin-based regimens (5,16).
pplying randomized clinical trials to PCI pharmacology
hoices. Bleeding complications are related to early and
-year mortality (21). Thus, attempts to decrease bleeding
omplications with better access techniques, arterial man-
gement strategies, and improved PCI pharmacology are
audable. If one believes that the CIAO trial does demon-
trate bleeding reduction with removal of the coronary
ntervention safety net, how would one apply these findings
o everyday clinical practice? The Northern New England
ardiovascular Consortium estimates that approximately
0% of all PCI fit the “elective” category (W. Piper and D. J.
alenka, personal communication, June 2, 2006). Thus,
rst, we must apply these results to only the 20% of patients
ndergoing a elective PCI; second, we must read their
ethods section and similarly exclude elective PCI patients
ith angiographic high-risk characteristics such as calcifi-
ation, long lesions, thrombus, small vessels, bifurcation
esions, and vein graft lesions that might lengthen procedure
ime to longer than the 11-min average seen in this study.
ne may estimate that approximately 50% of elective PCI
atients would have been angiographically excluded from
rials such as the CIAO and REMOVE trials, and so we
ay be left with a new PCI pharmacology paradigm that
ould apply to only 10% of our PCI population.
The history of interventional cardiology is one of apply-
ng new medications and technologies beyond the descrip-
ion of the clinical trials (22). Whereas that may be benign
n some situations, the application of a “no antithrombin”
pproach to higher risk PCI may be potentially life threat-
ning. Thus, we can applaud the researchers of the CIAO
rial for pushing the boundaries of elective PCI pharmacol-gy to new levels of minimalism in the valid hope of
educing bleeding complications; the reader, though, should
eed the investigators’ valid and important conclusion that
this paper is not intended to provide false reassurance. . . .”
nd, before we apply a “no antithrombin” approach to a
inority of PCI patients in future randomized clinical trials,
e may want to consider the relatively similar pathophysi-
logy of both elective and urgent coronary interventions and
nstead pursue the goal of replacing flawed first-generation
ntithrombins with better and safer antithrombin therapy.
eprint requests and correspondence: Dr. Harold L. Dauerman,
ardiac Unit, McClure 1, Fletcher Allen Health Care, 111
olchester Avenue, Burlington, Vermont 05401. E-mail: harold.
auerman@vtmednet.org.
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